Favini, C.
35  Ergebnisse:
Personensuche X
?
4

P1281: LIQUID BIOPSY PROVIDES COMPLEMENTARY INFORMATION TO ..:

Moia, R ; Favini, C ; Talotta, D...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431283/.  , 2022
 
?
5

Redefining the prognostic likelihood of chronic lymphocytic..:

Raponi S ; Ilari C ; Della Starza I...
info:eu-repo/semantics/altIdentifier/pmid/32064595.  , 2020
 
?
6

KMT2D mutations and TP53 disruptions are poor prognostic bi..:

Ferrero S ; Rossi D ; Rinaldi A...
info:eu-repo/semantics/altIdentifier/pmid/31537689.  , 2020
 
?
7

Biological and clinical implications of BIRC3 mutations in ..:

Diop F ; Moia R ; Favini C...
info:eu-repo/semantics/altIdentifier/pmid/31371416.  , 2020
 
?
8

Biological and clinical implications of BIRC3 mutations in ..:

Diop F ; Moia R ; Favini C...
info:eu-repo/semantics/altIdentifier/wos/WOS:000510846700035.  , 2020
 
?
9

Biallelic BIRC3 inactivation in chronic lymphocytic leukaem..:

Raponi S ; Del Giudice I ; Ilari C...
info:eu-repo/semantics/altIdentifier/wos/WOS:000462346300024.  , 2018
 
?
10

P1281: LIQUID BIOPSY PROVIDES COMPLEMENTARY INFORMATION TO ..:

R. Moia ; C. Favini ; D. Talotta...
http://journals.lww.com/10.1097/01.HS9.0000847988.92666.b7.  , 2022
 
?
12

Antitumor efficacy of the heparanase inhibitor SST0001 alon..:

Cassinelli, G. ; Lanzi, C. ; Tortoreto, M....
Biochemical Pharmacology.  85 (2013)  10 - p. 1424-1432 , 2013
 
?
 
1-15